Abstract: Use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing an inflammatory or immune disease are provided. Compounds of A1-A52, B1-B5, or C1-C36 are used in the preparation of a drug for treating and/or preventing diseases such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, vitiligo, dermatomyositis, alopecia areata, urticaria, multiple myositis, an interstitial lung disease, systemic lupus erythematosus, systemic sclerosis, and psoriasis.

Abstract: Provided in the present invention are a pan-KRAS degrading agent, and a preparation method therefor and the use thereof. Specifically, disclosed in the present invention are a small molecule compound for targeted degradation of the pan-KRAS protein, and a preparation method therefor and the use thereof as a therapeutic agent for preventing and/or treating cancers. The compound of the present invention can effectively degrade and/or inhibit the pan-KRAS protein in cells, and can be used in the preparation of a drug for treating and/or preventing relevant diseases or conditions mediated by pan-KRAS.

Abstract: Disclosed in the present invention are a KRAS G12D degradation agent, and a preparation method and use therefor. The KRAS G12D degradation agent in the present invention is a compound as shown in formula I or I?, and/or a stereoisomer, enantiomer, diastereomer, atropisomer, deuterated compound, hydrate, solvate, prodrug, and/or pharmaceutically acceptable salt thereof. The compound provided by the invention can effectively degrade and/or inhibit KRAS G12D protein in cells, and can be used for preparing a drug for treating and/or preventing related diseases or conditions caused by KRAS G12D mediation.

Abstract: A compound represented by formula I are provided. The stereoisomer, racemate, tautomer, isotopic label, prodrug or a pharmaceutically acceptable salt of the compound, and a pharmaceutical composition containing the compound, a preparation method, and medical use of the compound are further provided. The structure is as shown in formula I.

Abstract: Disclosed are an SOS1 degrading agent and a preparation method therefor and use thereof. Specifically, disclosed is a compound of formula I: S-L-E (I), wherein L is a linking chain, which links S and E by means of covalent bonds; E is a small molecule ligand of an E3 ubiquitin ligase complex. The compound of formula I of the present invention can degrade and/or inhibit SOS1 protein in cells, and can be used for the treatment and/or prevention of an SOS1-mediated disease or disorder, or a disease or disorder caused by the interaction of SOS1 with Ras or SOS1 with Rac.

Abstract: Disclosed are an SOS1 degrading agent and a preparation method therefor and use thereof. Specifically, disclosed is a compound of formula I: S-L-E(I), wherein L is a linking chain, which links S and E by means of covalent bonds; E is a small molecule ligand of an E3 ubiquitin ligase complex; and S is the structure shown in S7. The compound of formula I of the present invention can degrade and/or inhibit SOS1 protein in cells, and can be used for the treatment and/or prevention of an SOS1-mediated disease or disorder, or a disease or disorder caused by the interaction of SOS1 with Ras or SOS1 with Rac.

Abstract: A compound represented by formula I are provided. The stereoisomer, racemate, tautomer, isotopic label, prodrug or a pharmaceutically acceptable salt of the compound, and a pharmaceutical composition containing the compound, a preparation method, and medical use of the compound are further provided. The structure is as shown in formula I.